Sodium-glucose co-transporter 2 inhibitors use and the risks of genital and urinary tract infection: What should we know?
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have convincingly demonstrated efficacy in reducing cardiovascular (CV) and renal complications in patients with diabetes mellitus, chronic kidney disease, and heart failure. However, their use is also linked to the concern of some adverse events, t...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-07-01
|
| Series: | Tzu Chi Medical Journal |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/tcmj.tcmj_275_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|